Back to catalogue
№ 002 22 filings · 2021-04-16 → 2026-04-09

ASTRAZENECA PLC

AZN
Health Care Market cap £216,331.9m
Fair value range 13,300–14,900p Mid case · £219,000m
Absolute upside +1.2% vs current market cap
Conviction 4/5 confidence in fair call
Supports the call
  • Clean Reported/Core disclosure with explicit FY26 management guidance
  • Strong multi-year execution track record (16 Phase 3 wins in 2025, 43 approvals)
  • Forward P/E methodology converges with EV/EBITDA cross-check
Limits the call
  • Terminal P/E multiple is sensitive to peer-group framing (Big Pharma vs growth-pharma)
  • GBP/USD assumption materially affects per-share GBP fair value
Methodology

Forward P/E on Core EPS, cross-checked vs EV/EBITDA

In one line · bull case

Best-in-class oncology franchise plus the broadest late-stage pipeline in pharma support a credible path to $80bn revenue by 2030 with double-digit EPS compounding.

In one line · biggest risk

Concentration in Tagrisso/Imfinzi creates a mid-decade LoE cliff that pipeline assets must offset on schedule, against a backdrop of unresolved China legal and regulatory issues.

Drivers
AI exposure positive
Cyclicality low
Moat wide
Leverage medium
Earnings quality high
Management high
Trajectory stable

AstraZeneca PLC (AZN) — Investment Research Note

Executive summary

AstraZeneca is a top-tier global biopharmaceutical company focused on Oncology, Rare Diseases and BioPharmaceuticals (CVRM, R&I, V&I), now ~44% Oncology by revenue. Across the period covered, the group has executed an extraordinary turnaround: Total Revenue grew from $26.6bn (2020) through Vaxzevria-distorted 2021–22 to a clean $58.7bn in FY 2025 (+8% CER), Core EPS rose to $9.16 (+11% CER), and management delivered 16 positive Phase 3 readouts and 43 major-market approvals in 2025 2026-02 final results. The single most important point for valuation today is that AZN's "Ambition 2030" $80bn revenue target now looks credible given pipeline depth, 16 blockbuster medicines, and a catalyst-rich 2026 (>20 Phase 3 readouts expected) — so the question is no longer whether growth materialises but what multiple the market should pay for it.

Fair value estimate

  • Methodology: Forward P/E on Core (adjusted) EPS — appropriate for a large-cap pharma with stable cash generation, a deep recurring revenue base, and significant non-cash amortisation. Cross-checked against EV/EBITDA.
  • Key assumptions:
    • FY 2026E Core EPS: ~$10.20 (mid-point of "low double-digit %" guidance off $9.16 2026-02 final results)
    • GBP/USD: ~1.30 → FY 2026E Core EPS ~£7.85
    • Fair P/E range: 17x–19x forward Core EPS. AZN warrants a premium to traditional Big Pharma (Roche/GSK at 10–13x) given Oncology leadership, accelerating top-line, and a 100+ Phase 3 portfolio, but below GLP-1 darlings (Lilly/Novo).
    • 1,551m shares outstanding 2026-04 AGM result
  • Fair value range: £133 – £149 per share → implied market cap £206bn – £231bn, mid ~£219bn
  • Current market cap: £216,331.9m (≈ £139.5/share)
  • Absolute upside to mid-point: ~+1% — stock is essentially fairly priced, with bull case in the +7% region and bear case roughly -4%.

Sector context

  • Sector: Health Care / Pharmaceuticals & Biotechnology — confirmed.
  • Quality / growth / leverage: AZN is above peers on quality (deep moat, broad therapeutic franchise, leading oncology pipeline), above peers on growth (mid-to-high single-digit revenue, low double-digit EPS — Big Pharma average is low-mid single-digit), and broadly in line on leverage ($23.4bn net debt, ~1.2x EBITDA, A1/A+ ratings 2026-02 final results).
  • UK-listed peers: GSK plc (GSK.L), Hikma Pharmaceuticals (HIK.L). Indivior (INDV.L) is a smaller, lower-quality comparable. AZN is by far the largest and highest-quality UK pharma name.

Investment thesis

  • Oncology engine is the structural growth story: Oncology revenue grew 14% CER to $25.6bn in 2025 (44% of total), led by Tagrisso, Imfinzi (+28%), Calquence (+12%), Enhertu (+40%), and rapid uptake of Truqap (+68%) and Datroway. With Enhertu, Datroway and rilvegostomig pipelines extending into earlier lines and new tumour types, this franchise alone should compound double-digit for several years 2026-02 final results.
  • Pipeline density derisks the 2030 ambition: Management delivered 16 positive Phase 3 readouts in 2025, has >100 ongoing Phase 3 trials, and >20 Phase 3 readouts due in 2026, including transformative reads on baxdrostat (hypertension), elecoglipron (a Phase 2b GLP-1/GIP combo that just met both obesity and T2D primary endpoints in Feb 2026), gefurulimab, and anselamimab 2026-02 final results.
  • Listing harmonisation + China investment broaden investor base and de-risk geopolitics: NYSE ordinary share listing from Feb 2026 unlocks deeper US institutional ownership, while the $15bn China commitment through 2030 buys local goodwill amid a backdrop of unresolved investigations 2026-02 final results.

Key risks

  • Tagrisso & Imfinzi LoE concentration: Tagrisso ($7.3bn, 12% of sales) and Imfinzi ($6.1bn, 10%) are the two largest medicines; both face mid-to-late-decade patent and competition pressure. Generic challenges on Forxiga (already launched in UK, Japan; Brilinta in Q2 2025 caused a 38% Brilinta decline) demonstrate the franchise's exposure to LoE cliffs 2026-02 final results.
  • China legal & regulatory overhang: Former EVP and a former senior employee were indicted in Nov 2025 on unlawful collection of personal information, illegal trade and medical insurance fraud charges, and import-tax exposure of RMB 24m was paid as voluntary compensation. While AZ China was not indicted for fraud, reputational and access risks in a $6.7bn market remain elevated 2026-02 final results.
  • Pipeline-failure risk despite breadth: LATIFY (ceralasertib) primary endpoint missed; DUO-O Lynparza filings withdrawn; Saphnelo SC received a CRL from FDA; ALXN1840 was discontinued in 2025 (Wilson Disease). A single missed readout in a high-expectation asset (e.g., camizestrant, datopotamab deruxtecan in early-line) could compress the premium multiple meaningfully 2026-02 final results.

Value-trap signals

None identified. Revenue is growing, dividend is rising (declared FY 2025 $3.20, raised to $3.30 for 2026), free cash flow is robust ($14.6bn operating cash flow), net debt is falling, credit ratings were upgraded (Moody's to A1 in Q1 2025), and there are no signs of customer concentration, related-party transactions, or terminal-decline dynamics. This is a growth-at-a-reasonable-price story, not a value trap.

Conviction

4 / 5 — High

Anchors: (1) clean, audited financials with consistent multi-year disclosure including Reported and Core reconciliations; (2) FY 2026 guidance from management is explicit and credible given recent execution; (3) the methodology (forward P/E on core EPS) is the standard approach for Big Pharma and converges with EV/EBITDA cross-checks.

Caveats: (1) Pharma fair value depends heavily on assumed terminal multiple, which is sensitive to peer-group selection and to the market's appetite for "growth pharma"; (2) FX (GBP/USD) swings of 5% would move the per-share GBP fair value by a similar amount.